TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:41
Satsuma Pharmaceuticals Inc. ( STSA ) https://www.satsumarx.com
1.10USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-80.14%
STSA
SPY
36.71%
-71.87%
STSA
SPY
70.96%
STSA
0.00%
SPY
262.36%
STSA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
36.47
-4.90
1.83
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.58
0.08
0.97
-220.03
0.00
0.12
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
40.18
100.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.69
-227.30
-58.14
0.00
Other Earnings and Cash Flow Stats:
Satsuma Pharmaceuticals Inc. ( STSA ) Net Income TTM ($MM) is -56.32
Satsuma Pharmaceuticals Inc. ( STSA ) Operating Income TTM ($MM) is -58.12
Satsuma Pharmaceuticals Inc. ( STSA ) Owners' Earnings Annual ($MM) is -49.61
Satsuma Pharmaceuticals Inc. ( STSA ) Current Price to Owners' Earnings ratio is -2.43
Satsuma Pharmaceuticals Inc. ( STSA ) EBITDA TTM ($MM) is -56.49
Satsuma Pharmaceuticals Inc. ( STSA ) EBITDA Margin is 0.00%
Capital Allocation:
Satsuma Pharmaceuticals Inc. ( STSA ) has paid 0.00 dividends per share and bought back -1.297447 million shares in the past 12 months
Satsuma Pharmaceuticals Inc. ( STSA ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Satsuma Pharmaceuticals Inc. ( STSA ) Interest-bearing Debt ($MM) as of last quarter is 0
Satsuma Pharmaceuticals Inc. ( STSA ) Annual Working Capital Investments ($MM) are -21
Satsuma Pharmaceuticals Inc. ( STSA ) Book Value ($MM) as of last quarter is 37
Satsuma Pharmaceuticals Inc. ( STSA ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Satsuma Pharmaceuticals Inc. ( STSA ) has 19 million in cash on hand as of last quarter
Satsuma Pharmaceuticals Inc. ( STSA ) has 5 million of liabilities due within 12 months, and long term debt 1 as of last quarter
Satsuma Pharmaceuticals Inc. ( STSA ) has 33 common shares outstanding as of last quarter
Satsuma Pharmaceuticals Inc. ( STSA ) has 0 million USD of preferred stock value
Academic Scores:
Satsuma Pharmaceuticals Inc. ( STSA ) Altman Z-Score is -6.60 as of last quarter
Satsuma Pharmaceuticals Inc. ( STSA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Satsuma Pharmaceuticals Inc. ( STSA ) largest shareholder is Ikarian Capital, LLC owning 136059 shares at 0.15 ($MM) value
Ken Takanashi(an insider) Bought 22053581 shares of Satsuma Pharmaceuticals Inc. ( STSA ) for the amount of $20068758.71 on 2023-06-06
10.43% of Satsuma Pharmaceuticals Inc. ( STSA ) is held by insiders, and 57.90% is held by institutions
Satsuma Pharmaceuticals Inc. ( STSA ) went public on 2019-09-13
Other Satsuma Pharmaceuticals Inc. ( STSA ) financial metrics:
FCF:-51.61
Unlevered Free Cash Flow:-31.59
EPS:-1.23
Operating Margin:40.18
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-104.33
Beta:0.00
Buffet's Owners Earnings:-49.61
Price to Owner's Earnings:-2.43
About Satsuma Pharmaceuticals Inc. ( STSA ) :
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.